General
Preferred name
TRIPELENNAMINE
Synonyms
TRIPELENNAMINE CITRATE ()
2-(Benzyl(2-(dimethylamino)ethyl)amino)pyridine citrate (1:1) ()
Tripelennamine HCl ()
Pyribenzamine HCl ()
Pyribenzamine hydrochloride ()
TRIPELENNAMINE HYDROCHLORIDE ()
Tripelennamine ()
Tripelennamine (hydrochloride) ()
NSC-757360 ()
Tripelennamine chloride ()
PBZ-SR ()
Vetibenzamina ()
Azaron ()
Dehistin ()
NSC-409943 ()
Pyribenzamine ()
NSC-118946 ()
PBZ ()
P&D ID
PD009718
CAS
6138-56-3
154-69-8
22306-05-4
91-81-6
Tags
natural product
drug
available
Approved by
FDA
First approval
1948
Drug Status
withdrawn
approved
vet_approved
Drug indication
Hypersensitivity
Antihistaminic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tripelennamine is a first-generation antihistamine. It also has serotonin reuptake inhibitor (SRI) activity, and was used as the template molecule in the development of the selective serotonin reuptake inhibitor (SSRI) . In addition, tripelennamine has dopamine reuptake inhibitor (DRI) activity.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Ki Database
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
64
Molecular Weight
255.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
2
Aromatic Ring Count
2
cLogP
2.65
TPSA
19.37
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Metabolic Enzyme/Protease
Neuronal Signaling
Target
H1 receptor
HRH1
Endogenous Metabolite
Histamine Receptor
Indication
asthma, allergic rhinitis, urticaria
Disease Area
pulmonary, allergy
MOA
Histamine Receptor antagonist
ATC
D04AA04
R06AC04
Therapeutic Class
Antiallergic Agents
Source data
